Where is Industry Getting it Wrong? A Review of Quality Concerns Raised at Day 120 by the Committee for Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products
ABSTRACT – Purpose. The aim of this study was to identify common trends in the deficiencies identified in the quality part of the dossier during the evaluation of marketing authorisation applications for medicinal products for human use submitted through the EU’s centralised procedure. Methods. We...
Main Authors: | John Joseph Borg, Jean-Louis Robert, George Wade, George Aislaitner, Michal Pirozynski, Eric Abadie, Tomas Salmonson, Patricia Vella Bonanno |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2009-08-01
|
Series: | Journal of Pharmacy & Pharmaceutical Sciences |
Online Access: | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/6525 |
Similar Items
-
Analysis of the Medicinal Products for Human Use Authorised in the Russian Federation
by: V. V. Kosenko, et al.
Published: (2022-04-01) -
Evaluation and Authorisation of Medicinal Products in the EAEU — «RegLek — EAEU 2019»
by: article Editorial
Published: (2019-06-01) -
Authorisation for Fusafungine-Containing Medicines is Revoked
by: Z. A. Alacheva
Published: (2016-06-01) -
Characteristic aspects of marketing authorisation and quality assurance of bacteriophage medicinal products in the Russian Federation
by: D. S. Davydov, et al.
Published: (2023-06-01) -
Advanced Therapy Medicines Based on Oncolytic Viruses (Part I: Development and Authorisation of Products in China)
by: E. V. Melnikova, et al.
Published: (2021-10-01)